Galapagos, advised by Argo, raises EUR 296.2 million gross proceeds in a U.S. public Offering

Argo advised Galapagos, a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, on its underwritten public offering of 2,961,373 American Depositary Shares (“ADSs”), for gross proceeds of €296.2 million.